Biosafety startup Red Queen Bio uses AI technology to pre-design antibody drugs to combat unknown novel pathogens that may be designed or modified by AI systems in the future. The company, led by OpenAI, said it has raised $36 million so far. The company plans to begin human clinical trials of its avian influenza and other influenza virus family antibody drugs next year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.